Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Alnylam Pharmaceuticals stock

ALNY
US02043Q1076
A0CBCK

Price

260.12
Today +/-
+5.14
Today %
+2.10 %

Alnylam Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Alnylam Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Alnylam Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Alnylam Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Alnylam Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Alnylam Pharmaceuticals Stock Price History

DateAlnylam Pharmaceuticals Price
12/5/2024260.12 undefined
12/4/2024254.72 undefined
12/3/2024251.84 undefined
12/2/2024253.01 undefined
11/29/2024253.07 undefined
11/27/2024253.74 undefined
11/26/2024253.35 undefined
11/25/2024250.98 undefined
11/22/2024244.89 undefined
11/21/2024246.80 undefined
11/20/2024248.79 undefined
11/19/2024234.27 undefined
11/18/2024232.27 undefined
11/15/2024235.56 undefined
11/14/2024257.91 undefined
11/13/2024265.83 undefined
11/12/2024268.95 undefined
11/11/2024279.82 undefined
11/8/2024277.43 undefined
11/7/2024272.22 undefined
11/6/2024273.01 undefined

Alnylam Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Alnylam Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Alnylam Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Alnylam Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Alnylam Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Alnylam Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Alnylam Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Alnylam Pharmaceuticals’s growth potential.

Alnylam Pharmaceuticals Revenue, EBIT and net profit per share

DateAlnylam Pharmaceuticals RevenueAlnylam Pharmaceuticals EBITAlnylam Pharmaceuticals Net Income
2029e6.1 B undefined2.72 B undefined2.37 B undefined
2028e4.89 B undefined1.71 B undefined1.64 B undefined
2027e3.86 B undefined972.6 M undefined1.04 B undefined
2026e3.62 B undefined404.79 M undefined337.73 M undefined
2025e2.69 B undefined-53.9 M undefined-157.82 M undefined
2024e2.29 B undefined-123.47 M undefined-268.65 M undefined
20231.83 B undefined-282.18 M undefined-440.24 M undefined
20221.04 B undefined-785.1 M undefined-1.13 B undefined
2021844.3 M undefined-708.7 M undefined-852.8 M undefined
2020492.9 M undefined-828.4 M undefined-858.3 M undefined
2019219.8 M undefined-939.4 M undefined-886.1 M undefined
201874.9 M undefined-814.7 M undefined-761.5 M undefined
201789.9 M undefined-500.1 M undefined-490.9 M undefined
201647.2 M undefined-424.6 M undefined-410.1 M undefined
201541.1 M undefined-296 M undefined-290.1 M undefined
201450.6 M undefined-405 M undefined-360.4 M undefined
201347.2 M undefined-92.9 M undefined-89.2 M undefined
201266.7 M undefined-60.8 M undefined-106 M undefined
201182.8 M undefined-54.8 M undefined-57.6 M undefined
2010100 M undefined-41.9 M undefined-43.5 M undefined
2009100.5 M undefined-48.1 M undefined-47.6 M undefined
200896.2 M undefined-27.8 M undefined-26.2 M undefined
200750.9 M undefined-93.2 M undefined-85.5 M undefined
200626.9 M undefined-39.5 M undefined-34.6 M undefined
20055.7 M undefined-43.5 M undefined-42.9 M undefined
20044.3 M undefined-32.3 M undefined-35.4 M undefined

Alnylam Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000.010.030.050.10.10.10.080.070.050.050.040.050.090.070.220.490.841.041.832.292.693.623.864.896.1
---25.00420.0092.3192.004.17--18.00-19.51-28.796.38-18.0014.6389.36-16.85195.95124.6671.5422.8776.2825.1617.3534.866.5726.7224.70
--37,925.0030,340.005,834.623,034.001,580.211,517.001,517.001,850.002,298.483,227.663,034.003,700.003,227.661,704.4998.6588.5884.1583.4183.7082.9966.3056.5041.8939.3131.0224.88
00000000000000000.070.190.410.70.871.52000000
-0-0.03-0.04-0.04-0.03-0.09-0.03-0.05-0.04-0.06-0.11-0.09-0.36-0.29-0.41-0.49-0.76-0.89-0.86-0.85-1.13-0.44-0.27-0.160.341.041.642.37
-575.0029.6320.00-19.05150.00-69.4180.77-8.5132.5685.96-16.04304.49-19.4441.3819.5155.3116.43-3.16-0.7032.75-61.10-39.09-41.42-314.65207.7257.8644.53
19.319.319.321.931.938.741.141.64242.450.361.674.38485.690.6100.6109.3115118.5121.7124.91000000
----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Alnylam Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Alnylam Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                           
0.020.020.050.080.220.390.430.280.230.150.120.250.71.080.631.691.081.541.872.442.192.44
001.20.83.854.263.51.50.14.239.98.323.33418.84368.9125.3205.6228.21
0000000010.6000000000533.573.332.499.58
000000000000000024.156.375.286.412989.15
0111.71.72.98.66.16.94.22.63.99.716.621.740.173.780.362.888.1132.9126.38
0.020.020.050.080.220.40.440.290.250.150.130.250.751.110.671.761.21.722.612.812.692.98
0.54.811.710.612.213.819.218.318.314.619.816.421.727.8114.6181.9320.7646.4706.5733.6738.6725.79
0000074.883.9160.3120.4114.4142.2150.1279.8251.8324.813.9000000
0000000000000000000000
03.93.42.51.910.80.60.40000000000000
0000000000000000000000
0.12.42.82.93.16.37.78.600.80031.71.5151.634.253.432.985.8101.1115.5121.39
0.611.117.91617.295.9111.6187.8139.1129.8162166.5333.2281.1591230374.1679.3792.3834.7854.1847.18
0.020.040.070.10.240.490.550.480.390.280.290.421.081.391.261.991.572.43.413.643.553.83
                                           
18.155.20.20.30.40.40.40.40.40.40.50.60.80.90.9111.11.21.21.21.26
00.010.110.170.340.420.450.480.50.520.620.851.842.512.613.954.185.25.646.066.456.81
-4.5-29.5-63-105.9-140.5-226-252.2-299.8-343.3-401-507-596.2-956.6-1,246.7-1,656.8-2,147.7-2,841-3,727.1-4,585.4-5,438.2-6,569.3-7,009.59
-0.2-4.6-3.3-2.60.60.31.20.70.7-0.215.719.748.84.4-33.4-34.4-33.2-3.9-11.21.2-2.47.87
00000000000000000-32.7-32.4-34.4-42.3-31.24
0.010.030.050.060.20.20.20.180.160.120.130.270.941.260.921.771.31.441.020.59-0.16-0.22
0.71.50.924.13.82.612.59.35.84.45.915.116.854.528.459.749.95273.498.155.52
21.43.93.94.511.79.39.811.112.311.614.223.728.842.172.2112.7224.9392.8435.7587.4754.52
00.3110.711.164.187.588.481.662.932.433.856.516.535.143.77.177.8140.5186.682.4157.74
0000000000000000000000
00.60.81.93.23.80000000000000000
2.73.86.618.522.983.499.4110.71028148.453.995.362.1131.7144.3179.5352.6585.3695.7767.9967.79
000.010.010.010000000000.150.030.0300.190.681.021.02
0000000000000000000000
000.010.010.010.210.250.190.130.080.110.10.050.060.060.050.060.61.611.681.922.06
000.010.020.020.210.250.190.130.080.110.10.050.060.210.080.090.61.812.362.943.08
00.010.020.040.040.290.350.30.240.160.150.150.140.120.340.230.270.962.393.063.74.05
0.020.040.070.10.240.490.550.480.390.280.290.421.081.391.261.991.572.43.413.643.553.83
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Alnylam Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Alnylam Pharmaceuticals's financial health and stability.

Assets

Alnylam Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Alnylam Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Alnylam Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Alnylam Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-4-25-32-42-34-85-26-47-43-57-106-89-360-290-410-490-761-886-858-852-1,131-440
00234456459101119151361734474454
000001-5-5100000000000000
22616-225263-50-79-55-9-8-293517-245402-12-162-3510
08468384545423823924592145190305362361492811701
0000001000000012000244532
000000255-10000000120000
-1-12-19-16-2419665-72-84-87-115-68-165-189-307-382-562-278-615-641-541104
0-3-9-1-5-7-10-4-4-1-8-4-34-13-64-104-126-140-70-76-72-62
0-3-34-40-30-277171417823-130-548-321142-290272-417-435-273169-336
00-25-38-25-2692819228311-126-514-308207-186399-277-365-196241-274
0000000000000000000000
0-1501-2-60000000150-1200-302005001350
0.020.030.050.050.160.060.010000.090.20.740.620.031.240.070.850.30.250.260.15
0.020.020.050.050.170.0600000.090.20.740.620.181.120.070.8211.250.430.17
0-200000000000000004955003124
0000000000000000000000
157-2-4112-2286-54-62-4-1812210512451-224127-5032346-53
-1.9-15.9-28.6-18.4-29.6188.754.7-77-89-88.4-123.9-72.7-199.6-202.1-372.3-487-689.5-418.6-685.4-718.1-613.441.95
0000000000000000000000

Alnylam Pharmaceuticals stock margins

The Alnylam Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alnylam Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alnylam Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Alnylam Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Alnylam Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Alnylam Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Alnylam Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Alnylam Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Alnylam Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Alnylam Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Alnylam Pharmaceuticals Margin History

Alnylam Pharmaceuticals Gross marginAlnylam Pharmaceuticals Profit marginAlnylam Pharmaceuticals EBIT marginAlnylam Pharmaceuticals Profit margin
2029e83.02 %44.56 %38.81 %
2028e83.02 %34.87 %33.49 %
2027e83.02 %25.2 %26.87 %
2026e83.02 %11.18 %9.33 %
2025e83.02 %-2.01 %-5.88 %
2024e83.02 %-5.4 %-11.74 %
202383.02 %-15.43 %-24.08 %
202283.73 %-75.68 %-109.04 %
202183.39 %-83.94 %-101.01 %
202084.16 %-168.07 %-174.13 %
201988.58 %-427.39 %-403.14 %
201897.6 %-1,087.72 %-1,016.69 %
201783.02 %-556.28 %-546.05 %
201683.02 %-899.58 %-868.86 %
201583.02 %-720.19 %-705.84 %
201483.02 %-800.4 %-712.25 %
201383.02 %-196.82 %-188.98 %
201283.02 %-91.15 %-158.92 %
201183.02 %-66.18 %-69.57 %
201083.02 %-41.9 %-43.5 %
200983.02 %-47.86 %-47.36 %
200883.02 %-28.9 %-27.23 %
200783.02 %-183.1 %-167.98 %
200683.02 %-146.84 %-128.62 %
200583.02 %-763.16 %-752.63 %
200483.02 %-751.16 %-823.26 %

Alnylam Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Alnylam Pharmaceuticals earnings per share therefore indicates how much revenue Alnylam Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alnylam Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alnylam Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alnylam Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alnylam Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Alnylam Pharmaceuticals Revenue, EBIT and net profit per share

DateAlnylam Pharmaceuticals Sales per ShareAlnylam Pharmaceuticals EBIT per shareAlnylam Pharmaceuticals Earnings per Share
2029e47.28 undefined0 undefined18.35 undefined
2028e37.91 undefined0 undefined12.7 undefined
2027e29.92 undefined0 undefined8.04 undefined
2026e28.07 undefined0 undefined2.62 undefined
2025e20.82 undefined0 undefined-1.22 undefined
2024e17.74 undefined0 undefined-2.08 undefined
202314.64 undefined-2.26 undefined-3.52 undefined
20228.52 undefined-6.45 undefined-9.29 undefined
20217.12 undefined-5.98 undefined-7.2 undefined
20204.29 undefined-7.2 undefined-7.46 undefined
20192.01 undefined-8.59 undefined-8.11 undefined
20180.74 undefined-8.1 undefined-7.57 undefined
20170.99 undefined-5.52 undefined-5.42 undefined
20160.55 undefined-4.96 undefined-4.79 undefined
20150.49 undefined-3.52 undefined-3.45 undefined
20140.68 undefined-5.45 undefined-4.85 undefined
20130.77 undefined-1.51 undefined-1.45 undefined
20121.33 undefined-1.21 undefined-2.11 undefined
20111.95 undefined-1.29 undefined-1.36 undefined
20102.38 undefined-1 undefined-1.04 undefined
20092.42 undefined-1.16 undefined-1.14 undefined
20082.34 undefined-0.68 undefined-0.64 undefined
20071.32 undefined-2.41 undefined-2.21 undefined
20060.84 undefined-1.24 undefined-1.08 undefined
20050.26 undefined-1.99 undefined-1.96 undefined
20040.22 undefined-1.67 undefined-1.83 undefined

Alnylam Pharmaceuticals business model

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA-based therapeutics for the treatment of severe genetic and other diseases. The company was founded in 2002 by John Maraganore and Phillip Sharp and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Alnylam Pharmaceuticals SWOT Analysis

Strengths

Alnylam Pharmaceuticals Inc has several strengths that contribute to its competitive advantage in the market:

  • Strong pipeline of RNAi therapeutic candidates
  • Leading expertise in RNA interference (RNAi) technology
  • Partnerships with pharmaceutical and biotechnology companies to support research and development
  • Strong financial position and available funding for ongoing operations

Weaknesses

Despite its strengths, Alnylam Pharmaceuticals Inc also faces certain weaknesses that may hinder its growth:

  • Dependence on collaborations and partnerships for drug development and commercialization
  • Reliance on a limited number of therapeutic areas, which increases vulnerability to market fluctuations
  • High costs associated with research and development activities
  • Regulatory uncertainties and potential legal challenges related to the use of RNA interference technology

Opportunities

Alnylam Pharmaceuticals Inc can capitalize on the following opportunities to enhance its position in the industry:

  • Increasing demand for novel RNAi therapeutics in various disease areas
  • Expansion into emerging markets with significant unmet medical needs
  • Growing interest in personalized medicine and targeted therapies
  • Potential collaborations and partnerships with academic institutions and research organizations for further innovation

Threats

Alnylam Pharmaceuticals Inc faces the following threats that could impact its business and market position:

  • Intense competition from other pharmaceutical companies developing RNA-based therapeutics
  • Potential intellectual property disputes and legal challenges from competitors
  • Regulatory changes and stringent approval processes for RNAi drugs
  • Uncertainty in reimbursement policies and pricing pressures in the healthcare industry

Alnylam Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Alnylam Pharmaceuticals Revenue by Segment

Segmente2023202020192018
Net product revenues1.24 B USD---
Net revenues from collaborations546.19 M USD---
Product Revenues, Net-361.52 M USD-12.54 M USD
Royalty revenue40.63 M USD---
Research Services Obligation--21 M USD-
C5 License Obligation----

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Alnylam Pharmaceuticals Revenue by Segment

Segmente2023202020192018
Product Revenues, Net--166.54 M USD-
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Alnylam Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Alnylam Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Alnylam Pharmaceuticals shares outstanding

The number of shares was Alnylam Pharmaceuticals in 2023 — This indicates how many shares 124.906 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alnylam Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alnylam Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alnylam Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alnylam Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.91 -0.87  (4.01 %)2024 Q3
6/30/2024-1.1 -0.13  (88.19 %)2024 Q2
3/31/2024-1.21 -0.52  (56.9 %)2024 Q1
12/31/2023-1.35 -1.1  (18.47 %)2023 Q4
9/30/2023-1.36 1.15  (184.4 %)2023 Q3
6/30/2023-1.4 -2.21  (-58.31 %)2023 Q2
3/31/2023-1.8 -1.4  (22.24 %)2023 Q1
12/31/2022-1.91 -1.68  (12.09 %)2022 Q4
9/30/2022-1.78 -2.69  (-51.47 %)2022 Q3
6/30/2022-1.66 -2.29  (-37.75 %)2022 Q2
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the Alnylam Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

70/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

54

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees53
Percentage of women in management
Percentage of Asian employees22
Share of Asian management
Percentage of Hispanic/Latino employees6
Hispano/Latino Management share
Percentage of Black employees6
Black Management Share
Percentage of white employees63
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Alnylam Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
11.60749 % Capital World Investors14,971,3432,182,1076/30/2024
9.65529 % The Vanguard Group, Inc.12,453,397512,2736/30/2024
9.02115 % Fidelity Management & Research Company LLC11,635,4761,971,1106/30/2024
5.04982 % BlackRock Institutional Trust Company, N.A.6,513,264399,5056/30/2024
4.81507 % Wellington Management Company, LLP6,210,479-998,5266/30/2024
4.67720 % Baillie Gifford & Co.6,032,656-590,9216/30/2024
3.01679 % Capital International Investors3,891,059239,8426/30/2024
2.93083 % Dodge & Cox3,780,185-31,2956/30/2024
2.74061 % State Street Global Advisors (US)3,534,836343,4636/30/2024
2.62948 % T. Rowe Price Associates, Inc.3,391,498-197,8746/30/2024
1
2
3
4
5
...
10

Alnylam Pharmaceuticals Executives and Management Board

Mr. Tolga Tanguler

(50)
Alnylam Pharmaceuticals Chief Commercial Officer
Compensation 6.88 M

Ms. Indrani Franchini

(51)
Alnylam Pharmaceuticals Executive Vice President, Chief Legal Officer and Secretary
Compensation 5.41 M

Mr. Michael Bonney

(64)
Alnylam Pharmaceuticals Chief Compliance Officer, Director (since 2014)
Compensation 4.72 M

Dr. Yvonne Greenstreet

(60)
Alnylam Pharmaceuticals Chief Executive Officer, Director (since 2016)
Compensation 4.59 M

Dr. Akshay Vaishnaw

(60)
Alnylam Pharmaceuticals Part Time Chief Innovation Officer
Compensation 3.59 M
1
2
3
4

Alnylam Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Ionis Pharmaceuticals Stock
Ionis Pharmaceuticals
SupplierCustomer0,930,820,26-0,140,13-0,45
Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals
SupplierCustomer0,890,810,430,18-0,010,43
Benitec Biopharma Stock
Benitec Biopharma
SupplierCustomer0,880,880,180,430,44-0,18
Centogene Stock
Centogene
SupplierCustomer0,820,810,350,530,62-0,17
Regulus Therapeutics Stock
Regulus Therapeutics
SupplierCustomer0,820,710,630,820,35-0,20
Blackstone Stock
Blackstone
SupplierCustomer0,680,790,310,550,260,68
Silence Therapeutics ADR Stock
Silence Therapeutics ADR
SupplierCustomer0,670,740,180,430,45
Omnicom Stock
Omnicom
SupplierCustomer0,650,530,09-0,48-0,530,32
SBI Stock
SBI
SupplierCustomer0,600,570,32-0,20-0,480,09
Vir Biotechnology Stock
Vir Biotechnology
SupplierCustomer0,590,68-0,210,450,490,15
1
2

Most common questions regarding Alnylam Pharmaceuticals

What values and corporate philosophy does Alnylam Pharmaceuticals represent?

Alnylam Pharmaceuticals Inc represents values of innovation, collaboration, and patient-focused research. The company is dedicated to pioneering RNA interference (RNAi) therapeutics to treat debilitating diseases. Alnylam strives to improve patient outcomes through their robust pipeline of potential therapies. With a commitment to scientific excellence and rigorous clinical development, Alnylam aims to transform the lives of those affected by rare genetic diseases. Through strategic partnerships and an unwavering dedication to advancing the field of RNAi therapeutics, Alnylam Pharmaceuticals Inc continues to drive change in the pharmaceutical industry.

In which countries and regions is Alnylam Pharmaceuticals primarily present?

Alnylam Pharmaceuticals Inc is primarily present in the United States, Europe, and the Asia-Pacific region. The company has established a strong presence in these key markets to maximize its global reach and cater to a diverse patient population. By expanding its operations internationally, Alnylam Pharmaceuticals Inc aims to ensure widespread accessibility to its innovative therapies and transformative treatments. Consequently, the company has successfully expanded its footprint across multiple countries and regions, solidifying its position as a prominent player in the global biopharmaceutical industry.

What significant milestones has the company Alnylam Pharmaceuticals achieved?

Alnylam Pharmaceuticals Inc has achieved significant milestones since its inception. Some notable accomplishments include gaining approval from the U.S. Food and Drug Administration (FDA) for their groundbreaking RNA interference (RNAi) therapeutic, ONPATTRO®. This marked a major milestone in the field of RNAi therapeutics as it became the first-ever FDA-approved RNAi therapeutic. Furthermore, Alnylam has successfully launched and commercialized ONPATTRO® in the United States and several European countries. The company has also made advancements in its pipeline, developing potential treatments for various rare genetic diseases. Overall, Alnylam Pharmaceuticals Inc has made substantial progress and continues to drive innovation in the field of RNAi therapeutics.

What is the history and background of the company Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals Inc is a renowned biopharmaceutical company that specializes in RNA interference (RNAi) therapeutics. Founded in 2002, Alnylam has emerged as a trailblazer in the development of innovative RNAi-based treatments. The company's commitment to advancing cutting-edge science and research has propelled its success in transforming the field of RNAi therapeutics. Alnylam's extensive portfolio includes groundbreaking treatments for various diseases, utilizing its proprietary platform technology. With a strong focus on precision medicine and improving patient outcomes, Alnylam Pharmaceuticals Inc has firmly established itself as a leader in the biopharmaceutical industry.

Who are the main competitors of Alnylam Pharmaceuticals in the market?

The main competitors of Alnylam Pharmaceuticals Inc in the market include Moderna, Inc., Ionis Pharmaceuticals, Inc., and Arbutus Biopharma Corporation.

In which industries is Alnylam Pharmaceuticals primarily active?

Alnylam Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Alnylam Pharmaceuticals?

The business model of Alnylam Pharmaceuticals Inc revolves around developing innovative RNA interference (RNAi) therapeutics to address a wide range of genetically defined diseases. The company focuses on utilizing its proprietary RNAi technology platform to silence specific disease-causing genes, allowing for the development of targeted treatments. Alnylam aims to bring transformative medicines to patients by leveraging its expertise in RNAi and collaboration with strategic partners. Through this model, Alnylam Pharmaceuticals Inc aims to provide breakthrough therapies for patients suffering from various genetic disorders, ultimately improving their quality of life.

What is the P/E ratio of Alnylam Pharmaceuticals 2024?

The Alnylam Pharmaceuticals P/E ratio is -120.94.

What is the P/S ratio of Alnylam Pharmaceuticals 2024?

The Alnylam Pharmaceuticals P/S ratio is 14.2.

What is the Quality Investing of Alnylam Pharmaceuticals?

The Quality Investing for Alnylam Pharmaceuticals is 7/10.

What is the revenue of Alnylam Pharmaceuticals 2024?

The expected Alnylam Pharmaceuticals revenue is 2.29 B USD.

How high is the profit of Alnylam Pharmaceuticals 2024?

The expected Alnylam Pharmaceuticals profit is -268.65 M USD.

What is the business model of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for rare and genetic diseases. The company was founded in 2002 and is based in Cambridge, Massachusetts. Alnylam is known for its groundbreaking research and development of RNA interference technology. Alnylam's business model is based on the discovery, development, and commercialization of therapies for rare and genetic diseases through the use of its proprietary RNA interference (RNAi) technology platform, which selectively silences malfunctioning genes. The company holds a leadership position in RNAi therapy and is a frontrunner in the development of RNAi therapeutics for curable diseases. The company offers products for various diseases, including polyneuropathy, hereditary ATTR amyloidosis, porphyria, and hemophilia. The company's products help prevent lasting damage from these diseases and improve patients' quality of life. Alnylam has a robust pipeline of RNAi therapeutics targeting various disease areas. The company has several brands in development, including Givosiran for the treatment of acute intermittent porphyria (AIP), Patisiran for the treatment of polyneuropathy in patients with hATTR amyloidosis, Lumasiran for the treatment of primary hyperoxaluria type B, and Fitusiran for the treatment of hemophilia. The company benefits from developing a wide range of RNAi therapeutics that can be used in different disease areas. It also has a strong intellectual property pipeline that allows for long-term protection of its technologies. Alnylam also engages in collaborations with other companies and partners. The company has formed partnerships with Sanofi Genzyme and other companies to accelerate the development and commercialization of RNAi therapeutics. In addition to its RNA interference therapies, Alnylam is also building a platform for the development of other RNA therapy candidates, including bispecific antibodies, modified mRNAs, and small interfering RNA candidates, to further harness the potential of RNA technology. Overall, Alnylam's business model is based on the research and development of RNA therapeutics for rare and genetic diseases. The company has a robust pipeline of RNAi therapeutics and plans to develop other forms of RNA therapies as well. Alnylam is a leading company in this emerging field and will continue to drive innovation in the future to help patients with curable diseases.

What is the Alnylam Pharmaceuticals dividend?

Alnylam Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Alnylam Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Alnylam Pharmaceuticals or the company does not pay out a dividend.

What is the Alnylam Pharmaceuticals ISIN?

The ISIN of Alnylam Pharmaceuticals is US02043Q1076.

What is the Alnylam Pharmaceuticals WKN?

The WKN of Alnylam Pharmaceuticals is A0CBCK.

What is the Alnylam Pharmaceuticals ticker?

The ticker of Alnylam Pharmaceuticals is ALNY.

How much dividend does Alnylam Pharmaceuticals pay?

Over the past 12 months, Alnylam Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alnylam Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Alnylam Pharmaceuticals?

The current dividend yield of Alnylam Pharmaceuticals is .

When does Alnylam Pharmaceuticals pay dividends?

Alnylam Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Alnylam Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alnylam Pharmaceuticals located?

Alnylam Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alnylam Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alnylam Pharmaceuticals from 12/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did Alnylam Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of Alnylam Pharmaceuticals in the year 2023?

In the year 2023, Alnylam Pharmaceuticals distributed 0 USD as dividends.

In which currency does Alnylam Pharmaceuticals pay out the dividend?

The dividends of Alnylam Pharmaceuticals are distributed in USD.

All fundamentals about Alnylam Pharmaceuticals

Our stock analysis for Alnylam Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alnylam Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.